GotReceipts tracks public buy and sell signals for AbbVie (ABBV)
and measures outcomes over matched windows.
For this ticker model, performance vs the S&P 500 is based on BUY/ADD calls only.
SELL/REDUCE calls are graded directionally and shown as Correct, Incorrect, or Pending.
That way, you can quickly see whether following public buy calls added value versus simply holding the index.
Do ABBV stock predictions beat the S&P 500?
No. Across 3 scored BUY/ADD calls, average return is -13.4% versus +4.8% for the S&P 500, for -18.2% alpha.
Who has the best track record predicting AbbVie?
Lori Calvasina currently ranks #1 on ABBV, with -12.9% average buy return versus +2.7% for the S&P 500 (-15.6% alpha) across 1 scored buy calls.
Is ABBV overvalued or undervalued?
Public prediction track records currently lean cautious on ABBV: buy calls have underperformed the index by +18.2% on average.
Should I follow analyst ratings on ABBV?
Use analyst and public-figure calls as one input, not a standalone signal. GotReceipts shows historical outcomes versus the S&P 500 so you can judge signal quality before acting.